Table 1 (abstract P004). Patient characteristics
From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)
| Â | Patients with pulmonary complications | Patients without pulmonary complications | P-value |
|---|---|---|---|
Patient number | 65 | 849 | Â |
Observation years total (IQR) | 7.6 (4.3-10.2) | 5.1 (2.4-9.1) | 0.002 |
Age diagnosis SJIA (IQR) | 3.7 (2.3-5.6) | 5.3 (2.9-9.3) | <0.001 |
Patients with non-pulmonary AE/ESI | 56 (86.2%) | 287 (33.8%) | <0.001 |
Synthetic DMARDs ever | 52 (80.0%) | 690 (81.3%) | 0.745 |
Anti-TNF ever | 25 (38.5%) | 307 (36.2%) | 0.691 |
Anti-IL1 ever | 29 (44.6%) | 332 (39.1%) | 0.430 |
Tocilizumab ever | 36 (55.4%) | 345 (40.6%) | 0.026 |
Rituximab ever | 20 (30.8%) | 49 (5.8%) | <0.001 |